Unlock instant, AI-driven research and patent intelligence for your innovation.
DPP-IV inhibitor
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A technology selected from, compounds, applied in the field of medicine, can solve the problems of short half-life, inactivation, etc.
Active Publication Date: 2013-03-06
GUANGZHOU INST OF BIOMEDICINE & HEALTH CHINESE ACAD OF SCI +1
View PDF2 Cites 1 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
Treatment based on GLP-1 can effectively control blood sugar, but as a substrate of DPP-IV, GLP-1 has a short half-life and will be rapidly cut and inactivated by DPP-IV within 1-2 minutes after secretion
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
[0081] Urea (1mol, 60g) was added to a 250ml dry single-necked round bottom flask, heated to 160°C in an oil bath to melt, and (0.13mol, 20g) methyl 3-aminothiophene-2-carboxylate was added, and the mixture was heated at 190- Heat and react at 200°C for 3 hours, cool, add 500ml of 10% aqueous sodium hydroxide solution, stir evenly, filter with suction, wash with 5-10% aqueous sodium hydroxide solution, and adjust the pH of the filtrate to 6.5 with 2N HCl solution in an ice bath. A white solid was precipitated, filtered with suction, washed with ice and water, and dried to obtain 12.5 g of a white solid with a yield of 59%.
[0097] Compound 2-1 was used to replace compound 1-1 in Example 1, and the synthesis method was referred to Example 1 to prepare compound 2 as a light yellow solid with a yield of 45%.
[0098] 1 H-NMR (400MHz, CD 3 OD): δ1.25(1H, m), 1.75(1H, m), 1.77(1H, m), 1.96(1H, m), 2.03(1H, m), 2.33(3H, s), 2.71(1H , m), 2.81(1H, s), 2.89(1H, m), 3.21(1H, m), 3.42(2H, m), 5.55(2H, ABq), 7.08(1H, d, J=8Hz), 7.39(1H, t, J=7.6Hz), 7.56(1H, t, J=7.8Hz), 7.59(1H, s), 7.69(1H, d, J=7.6Hz); MS: 380.1[M+H + ], 402.1 [M+Na + ].
[0104] Add compound 3-1 (77.5g, 0.5mol), methyl cyanoacetate (99.1g, 1mol) and 50ml of methanol into a 250ml round bottom flask, add 1ml of DMF and 5ml of triethylamine dropwise under ice-cooling, and heat to 70°C After reacting for 3 hours, the solvent was evaporated under reduced pressure, and the residue was treated with 1 L of cold water and stirred to obtain a beige precipitate, which was filtered with suction, washed with cold water, and dried to obtain 113 g of gray solid compound 3-2 with a yield of 79.6%.
[0107] Dissolve the compound 3-2 (9.5g, 6mmol) obtained in the above step in 300ml of dry dichloromethane, cool to -60°C, add 9g of chlorosulfonyl isocy...
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
PUM
Login to View More
Abstract
The invention relates to a hybrid pyrimido ketone DPP-IV inhibitor shown as a formula I as well as salts, a preparation method, compounds and application thereof in the prevention or treatment of diseases that benefit from the DPP-IV inhibitor. A preparation process of the DPP-IV inhibitor is simple, easily-obtained in raw materials and suitable for industrial large-scale production; and in-vitro and in-vivo experiments verify that the DPP-IV inhibitor has very good selective inhibition effect to DPP-IV, nearly has no influence on activities of DPP-VIII and DPP-IX at the same time of effectively inhibiting the DPP-IV activity, lower toxicity after prepared medicine development, stronger effect and longer acting time compared with the effect of a medicineAlogliptin with the same mechanism and shows excellent effects of reducing the blood sugar and increasing the insulin sensitivity. The formula I is shown as follows.
Description
technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to a compound or a salt thereof with a heterocyclic pyrimidinone as a core nucleus, a preparation method, a composition thereof, and this type of compound as a dipeptidyl peptidase (DPP-IV) inhibitor Use in the prophylaxis or treatment of a disease which would benefit from inhibition of DPP-IV. Background technique [0002] Diabetes Mellitus (DM) is a metabolic disease with multiple etiologies, which is caused by an absolute or relative deficiency of insulin, resulting in an increase in blood sugar and causing metabolic disorders in the body. It can be divided into insulin-dependent diabetes mellitus (insulin-dependent diabetes mellitus, IDDM, type I diabetes) and noninsulin-dependent diabetes mellitus (NIDDM, type II diabetes), of which type II diabetes is the most common, accounting for diabetes patients more than 90 percent. At present, most of the research on diab...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to View More 
Login to View More